BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Hovione Licenses Inhaler Technology for Influenza Drug to Sankyo Company, Ltd. (SKXOF.PK) and Biota Holdings Limited (BTA.AX)


3/5/2007 12:22:01 PM

LOURES, Portugal, March 5 /PRNewswire/ -- Hovione announced today the signature of an agreement where Sankyo Company Ltd, (Tokyo, Japan) and Biota Holdings Ltd (Melbourne, Australia) have jointly licensed Hovione's dry powder inhaler technology for the delivery of long acting neuraminidase inhibitors (LANI) owned by Sankyo and Biota, which are active against the influenza virus. An improvement over other approved medicines which have to be taken repeatedly, is that this novel compound is expected to remain active for several days and require to be taken once only. Hovione retains all inhaler rights outside the field of influenza.

Under the agreement, Hovione has developed a low-cost disposable inhaler, Twin Caps, specifically for this indication. In addition, Hovione carried out inhaler compatibility studies and comprehensive formulation development to demonstrate that the lead clinical candidate CS-8958 can be delivered by inhalation. Sankyo and Biota are responsible for the clinical development of the drug product, which is expected to start in the near future. CS-8958 has already completed phase I clinical trial in a prototype inhaler.

Peter Villax, Hovione Vice-President said, "This agreement is the confirmation that Hovione is recognized as a reliable partner in inhalation product development. We are the only independent company with expertise in every aspect of inhalation, from chemical development to particle design, from device to formulation development."

Peter Cook, Biota CEO said, "We will now be able to accelerate both the program with Sankyo and marketing this potentially important new product to other licensees. Biota has an impressive pipeline in anti-viral drugs and we expect that inhaled LANIs will offer further effective and convenient first line of defense against the influenza virus."

Hovione is a specialist company in Active Pharmaceutical Ingredient (API) manufacturing and inhaled formulation development. Through its expertise in API processing, Hovione has acquired significant know-how in particle design and engineering. This knowledge has permitted Hovione to offer a unique range of compliant services in API process development, particle design and inhalation formulations. Development services are available through Hovione facilities in Loures, Portugal and in New Jersey, USA.

For further information about Hovione, please visit the Hovione site at www.hovione.com or contact Corporate Communications (Isabel Pina, + 351 21 982 9362, e-mail: hello@hovione.com)

Hovione

CONTACT: Isabel Pina of Hovione, +351-21-982-9362, or hello@hovione.com



Read at BioSpace.com

   
Influenza

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES